Use of antimuscarinics in the elderly

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 459-465

  Patel, Bhavin ^a   Bavendam, Tamara ^b   Badlani, Gopal ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b PFIZER INC   (United States)

Author keywords

Anticholinergics; Elderly; Overactive bladder

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; DARIFENACIN; DIRECTLY ACTING MUSCLE RELAXANT; DIURETIC AGENT; FESOTERODINE; LAXATIVE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NARCOTIC AGENT; OXYBUTYNIN; PLACEBO; PROSTAGLANDIN INHIBITOR; SCOPOLAMINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; VASOPRESSIN DERIVATIVE; BENZOFURAN DERIVATIVE; PYRROLIDINE DERIVATIVE;

ANAMNESIS; BLADDER TRAINING; BLURRED VISION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; ELECTROENCEPHALOGRAM; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HEART DISEASE; HUMAN; MUSCLE RESECTION; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PELVIC FLOOR MUSCLE TRAINING; PHYSICAL EXAMINATION; PREVALENCE; PSYCHOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY URGENCY; XEROSTOMIA; AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; BENZOFURANS; HUMANS; MUSCARINIC ANTAGONISTS; PYRROLIDINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 70349325672     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.55     Document Type: Review

References (31)

1. Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., Kerrebroeck, P., and Sand, P. (2006) Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol. Urodyn. 25, 293
2. Stewart, W.F., Van Rooyen, J.B., Cundiff, G.W., et al. (2003) Prevalence and burden of overactive bladder in the United States. World J. Urol. 20, 327-336. (Pubitemid 44175300)
3. McGhan, W.F. (2001) Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am. J. Manag. Care 7(2 Suppl), S62-75.
4. Brown, J.S., McGhan, W.F., and Chokroverty, S. (2000) Comorbidities associated with overactive bladder. Am. J. Manag. Care 6(11 Suppl), S574-579.
5. Hu, T.W., Wagner, T.H., Bentkver, J.D., LeBlanc, K., Piancentini, A., Stewart, W.F., Corey, R., Zhou, S.Z., and Hunt, T.L. (2003) Estimated economic costs of overactive bladder in the United States. Urology 61(6), 1123-1128. (Pubitemid 36693985)
6. Milsom, I., Abrams, P., Cardozo, L., Roberts, R.G., Thuroff, J., and Wein, A.J. (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int. 87, 760-766. (Pubitemid 34204313)
7. Steers, W.D. (2002) Pathophysiology of overactive bladder and urge incontinence. Rev. Urol. 4(Suppl 4), S7-S18.
8. Andersson, K.E. (2002) Bladder activation: afferent mechanisms. Urology 59(5 Suppl 1), 43-50.
9. Wound, Ostomy, and Continence Nurses Society (2003) Identifying and treating reversible causes of urinary incontinence. Ostomy Wound Manage. 49(12), 28-33.
10. Siroky, M.B. (2004) The aging bladder. Rev. Urol. 6(Suppl 1), S3-7.
11. Garcia, A.D. (2008) The effect of chronic disorders on sleep in the elderly. Clin. Geriatr. Med. 24(1), 27-38.
12. Burgio, K.L., Locher, J.L., Goode, P.S., Hardin, J.M., McDowell, B.J., Dombrowski, M., and Candib, D. (1998) Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 280(23), 1995-2000. (Pubitemid 28562677)
13. Burgio, K., Locher, J.L., and Goode, P.S. (2000) Combined behavioral and drug therapy for urge incontinence in older women. J. Am. Geriatr. Soc. 48, 370-374. (Pubitemid 30207759)
14. Srikrishna, S., Robinson, D., Cardozo, L., and Vella, M. (2007) Management of overactive bladder syndrome. Postgrad. Med. J. 83(981), 481-486.
15. Andersson, K.E: (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 3, 46-53
16. Wei, J., Walton, E.A., Milici, A., and Buccafusco, J.J. (1994) M1-M5 Muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J. Neurochem. 63, 815-821. (Pubitemid 2131165)
17. Anagnostaras, S.G., Murphy, G.G., Hamilton, S.E., Mitchell, S.L., Rahnama, N.P., Nathanson, N.M., and Silva, A.J. (2003) Selective cognitive dysfunction in acetylcholine muscarinic receptor mutant mice. Nat. Neurosci. 6(1), 51-58. (Pubitemid 36026332)
18. Kay, G.G. and Granville, L.J. (2005) Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin. Ther. 27(1), 126-138.
19. Chapple, C., DuBeau, C., Ebinger, U., Rekeda, L., and Viegas, A. (2007) Darifenacin treatment of patients > 65 years with overactive bladder: results of a randomized controlled, 12 week trial. Curr. Med. Res. Opin. 23(10), 2347-2358. (Pubitemid 350033436)
20. Ouslander, J.G. (2004) Management of overactive bladder. N. Engl. J. Med. 350, 786-799.
21. Yarker, Y.E., Goa, K.L., and Fitton, A. (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6(3), 243-262.
22. Birns, J., Lukkari, E., and Malone-Lee, J.G. (2000) A randomized controlled trial comparing the efficacy of controlled release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. 85, 797-798.
23. Davila, G.W., Daugherty, C.A., Sanders, S.W., for the Transdermal Oxybutyn in Study Group (2001) A short-term, multicenter randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J. Urol. 166, 140-145.
24. Staskin, D.R., Dmoschoski, R.R., Sand, P.K., MacDiarmid, S.A., Caramelli, K.E., Thomas, H., and Hoel, G. (2009) Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter trial. J. Urol. 181(4), 1764-1772.
25. Zinner, N.R., Mattiasson, A., and Stanton, S.L. (2002) Efficacy, safety and tolerability of extended release once-daily tolterodine treatment for overactive bladder in older versus yournger patients. J. Am. Geriatr. Soc. 50, 799-807. (Pubitemid 34496674)
26. Halaska, M., Ralph, G., Wiedemann, A., Primus, G., Ballering-Bruhl, B., Hofner, K., and Jonas, U. (2003) Controlled, double blind, multicentre clinical trial to investigate the long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol. 20(6), 392-399. (Pubitemid 44175311)
27. Hill, S., Elhilali, M., Millard, R.J., Dwyer, P.L., Lheritier, K., Kawakami, F.T., and Steel, M. (2007) Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr. Med. Res. Opin. 23(11), 2697-2704. (Pubitemid 350146407)
28. Cardozo, L. and Dixon, A. (2005) Increased warning time with darifenacin: a new concept in the management of urinary urgency. J. Urol. 173(4), 1214-1218. (Pubitemid 40380539)
29. Lipton, R.B., Kolodner, K., and Wesnes, K. (2005) Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol. 173(2), 493-498.
30. Wagg, A., Wyndaele, J.J., and Sieber, P. (2006) Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am. J. Geriatr. Pharmacother. 4(1), 14-24. (Pubitemid 43758181)
31. Cardozo, L., Lisec, M., Millard, R., van Vierssen Trip, O., Kuzmin, I., Drogendijk, T.E., Huang, M., and Ridder, A.M. (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. 172, 1919-1924. (Pubitemid 39363090)